References
- Global market for nanomedicine expected to grow at 12.3% compound annual growth rate to reach $177.60 billion in 2019. www.azonano.com/news.aspx?newsID=29127
- Impax and Durect sign a US$63 million agreement to develop and commercialize Durect’s ELADUR® pain patch. http://investors.impaxlabs.com/Media-Center/Press-Releases/Press-Release Details/2014/Impax-and-DURECT-Sign-a-63-Million-Agreement-to-Develop-and-Commercialize-DURECTs-ELADUR-Pain-Patch/default.aspx
- Elixir Medical announces first commercial implant of the DESolve® Novolimus eluting coronary scaffold system in Europe. http://elixirmedical.com/index.php?page = us-news-and-events
- NanoViricides announces that it has raised $20 million in a registered direct offering. www.nanoviricides.com
- Adamis Pharmaceuticals announces completion of acquisition. www.adamispharmaceuticals.com/investors-newsroom.php
- Scholar Rock announces collaboration with Johnson & Johnson innovation to discover and develop novel biologics for the treatment of autoimmune diseases and cancer. http://scholarrock.com/news/releases/2014%200108%20Scholar-Rock-J&J.html
- Health ministry to amend drugs and cosmetics rules to include new drug delivery systems as new drug. www.pharmabiz.com/NewsDetails.aspx?aid=79640&sid=1
- MedacPharma, Inc. secures US FDA acceptance of a new drug application for methotrexate-containing autopen. www.medacpharma.com/medac-pharma-inc-secures-fda-acceptance-of-a-new-drug-application-nda-for-methotrexate-containing-autopen
- Salix announces acceptance of new drug application filing for budesonide foam in patients with distal ulcerative colitis. www.salix.com/news-media/news/index/acceptance-of-nda-filing-for-budesonide-foam-in-distal-ulcerative-colitis
- Avanir pharmaceuticals announces submission of new drug application for AVP-825 for the acute treatment of migraine. http://ir.avanir.com/phoenix.zhtml?c=61699&p=irol-newsArticle&ID=1895311
- Endo and BioDelivery Sciences announce positive top-line results from the Phase III clinical trial of BEMA buprenorphine in opioid naive patients with chronic pain. www.endo.com/news-events
- Alkermes announces advances with its late-stage CNS pipeline. http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-corporateNews&nyo=0
- Oramed announces successful FDA Phase IIa clinical trial results. www.drugs.com/clinical_trials/oramed-announces-successful-fda-phase-2a-clinical-trial-results-16437.html
- Progenics pharmaceuticals presents positive data from a Phase II trial of PSMA antibody-drug conjugate in patients with chemotherapy experienced metastatic castrate resistant prostate cancer. http://ir.progenics.com/releasedetail.cfm?ReleaseID=822204
- Celsion corporation announces updated overall survival results from Phase III HEAT study of ThermoDox® in primary liver cancer. http://investor.celsion.com/releasedetail.cfm?ReleaseID=821197
- Cynapsus announces completion of human healthy volunteer crossover study results for APL-130277. www.cynapsus.ca/news.php?article=301
- Roche reports new method for efficiently transporting antibodies across the blood–brain barrier. www.roche.com/media/media_releases/med_pha_2014--01--08.htm
- Antibiotic ‘smart bomb’ can target specific strains of bacteria. www.sciencedaily.com/releases/2014/01/140130110953.htm
- On-demand vaccines possible with engineered nanoparticles. www.sciencedaily.com/releases/2014/01/140107134312.htm
- ORAMED LTD: AUS 2013237663 (2013).
- Sabbadini RA, Garland WA, Stoller GL: US 8614103 (2013).